Philip Morris International
PM
$187.15
-0.08%
Philip Morris International Inc. (PM) is a global tobacco company that sells cigarettes and reduced-risk products, including heated tobacco (IQOS), vapes (Veev), and oral nicotine (Zyn), primarily outside the United States. As a dominant player in the industry, PMI leverages its iconic Marlboro brand and its leadership in smoke-free alternatives, having acquired Swedish Match in 2023 to strengthen its oral nicotine portfolio. The current investor narrative centers on PMI's strategic pivot toward reduced-risk products, which are driving growth and reshaping its revenue mix, while regulatory developments, such as the FDA's stance on nicotine pouches, and the company's ability to sustain margin expansion remain key points of debate.…
PM
Philip Morris International
$187.15
Related headlines
Investment Opinion: Should I buy PM Today?
Based on the analysis, PM is rated a Buy. The company's strong revenue growth, successful transition to reduced-risk products, and attractive valuation relative to growth make it a compelling investment. The average analyst target of $203.80 implies a 6.2% upside, and the high target of $225.00 suggests even greater potential. The thesis is supported by PM's ability to grow revenue while maintaining high margins, positioning it well for long-term value creation.
Sign up to view all
PM 12-Month Price Forecast
The AI assessment is bullish on PM, driven by its strong revenue growth and successful transition to reduced-risk products. The low PEG ratio suggests the stock is undervalued relative to its growth potential, and analyst targets imply upside. However, regulatory risks and high payout ratio warrant a medium confidence level. The stance would be upgraded to high confidence if regulatory clarity improves and growth accelerates, while a downgrade would occur if regulatory actions severely impact Zyn or if revenue growth falls below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $203.80 and implied upside of +8.9% versus the current price.
Average Target
$203.80
0 analysts
Implied Upside
+8.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $225
Analyst target range
PM is covered by 15 analysts, with a consensus recommendation that leans bullish, as evidenced by recent actions from major firms: Morgan Stanley maintains an Overweight rating, Needham and Citigroup have Buy ratings, while UBS and Jefferies hold Neutral/Hold stances. The average target price is $203.80, implying a 6.2% upside from the current price of $191.89. The target range spans from $175.00 (low) to $225.00 (high), with the high target suggesting a 17.2% upside, likely reflecting optimism about reduced-risk product growth and margin expansion, while the low target implies a -8.8% downside, possibly pricing in regulatory risks or competitive pressures.
Drowning in data?
Find the real signal!
Bulls vs Bears: PM Investment Factors
PM presents a compelling investment case with strong revenue growth, a successful pivot to reduced-risk products, and an attractive valuation relative to growth. The bull case is supported by solid fundamentals, including high margins and a low PEG ratio, while the bear case centers on regulatory risks, high payout ratio, and negative equity. Currently, the bull case has stronger evidence, as the company's growth trajectory and valuation support further upside. The most critical tension is whether reduced-risk products can sustain their growth momentum and offset regulatory and competitive pressures, which will determine if PM can achieve its analyst targets.
Bullish
- Strong Revenue Growth: PM's Q1 2026 revenue grew 9.09% YoY to $10.146 billion, up from $9.301 billion in Q1 2025, marking the fifth consecutive quarter of growth. This consistent expansion, driven by reduced-risk products, demonstrates the company's successful transition beyond traditional cigarettes.
- Reduced-Risk Products Driving Mix: Reduced-risk products generated $4.379 billion in Q1 2026, representing 43.2% of total revenue, up from 38.5% in the prior year. This shift toward higher-growth smoke-free alternatives like IQOS and Zyn is a key catalyst for future margin expansion and volume growth.
- Attractive Valuation with PEG of 0.36: With a trailing PE of 22.06x and forward PE of 20.93x, PM trades at a modest premium to the broader market, but the PEG ratio of 0.36x indicates the stock is undervalued relative to its expected earnings growth. This suggests the market is not fully pricing in the company's growth potential.
- High Gross and Operating Margins: PM's gross margin stands at 67.1%, and operating margin at 36.7%, reflecting strong pricing power and operational efficiency. These high margins provide a buffer against input cost inflation and support continued investment in reduced-risk product innovation.
Bearish
- Regulatory Risk on Nicotine Pouches: The FDA's recent decision on nicotine pouches poses a significant threat to PM's Zyn brand, a key growth driver. Any restrictions on marketing or sales could dampen the growth of reduced-risk products, which currently contribute 43.2% of revenue.
- High Payout Ratio Limits Flexibility: PM's payout ratio is 76.0%, leaving limited room for dividend increases or share buybacks. This high payout, combined with a dividend yield of 3.46%, may constrain financial flexibility and could be a concern if earnings growth slows.
- Negative Equity and High Debt: PM's debt-to-equity ratio is -4.89, indicating negative shareholders' equity, a result of significant debt and share repurchases. This financial structure increases vulnerability to interest rate hikes and may limit future borrowing capacity.
- Relative Underperformance vs. Market: While PM is up 15.76% over the past year, it has underperformed the S&P 500, which gained 18.56% in the same period. Over the past month, PM fell 3.30% while the market rose 5.47%, indicating negative relative strength of -8.77%.
PM Technical Analysis
PM is currently in a well-defined uptrend, with the stock up 15.76% over the past year and trading at $191.89, which is 92.4% of its 52-week range (low of $142.11, high of $207.76). This positioning near the upper end of its range suggests strong momentum, though it also implies the stock may be approaching overbought conditions. The 52-week high of $207.76 was set in late July 2026, and the current price is 7.6% below that peak, indicating a modest pullback from recent highs.
Beta
0.40
0.40x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$142-$208
Price range past year
Annual Return
+12.0%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | -1.9% | +2.0% |
| 3m | +6.4% | +1.0% |
| 6m | +10.3% | +11.8% |
| 1y | +12.0% | +18.1% |
| ytd | +16.7% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PM's revenue growth has been solid, with Q1 2026 revenue of $10.146 billion, up 9.09% year-over-year, and the company has consistently grown revenue over the past five quarters, from $9.301 billion in Q1 2025 to $10.146 billion in Q1 2026. The growth is driven by reduced-risk products, which generated $4.379 billion in revenue in the latest quarter, representing 43.2% of total revenue, while combustible products contributed $5.767 billion. This shift toward smoke-free alternatives is a key growth driver, as these products are growing faster than traditional cigarettes.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Given that PM has positive net income, the PE ratio is the most appropriate valuation metric. The trailing PE is 22.06x, while the forward PE is 20.93x, indicating that the market expects earnings growth of approximately 5.4% over the next year. This modest forward discount suggests a stable growth outlook. The PEG ratio of 0.36x implies that the stock is undervalued relative to its expected earnings growth, making it an attractive value proposition for a consumer staples company.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include PM's high payout ratio of 76.0%, which limits financial flexibility and could be a concern if earnings growth slows. The company's negative equity (debt-to-equity of -4.89) indicates a leveraged balance sheet, with significant debt that could become burdensome if interest rates rise. Additionally, the current ratio of 0.96 suggests potential liquidity constraints, though the strong free cash flow of $10.666 billion TTM provides some cushion. Revenue concentration in combustible products (56.8% of Q1 2026 revenue) exposes PM to declining cigarette volumes, which could pressure margins if not offset by reduced-risk growth.